Soleno Therapeutics (SLNO) Price & Analysis

Compare

783 Followers

SLNO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$41.50 - $90.32

Previous CloseN/A

Volume118.06K

Average Volume (3M)1.34M

Market Cap

$4.38B

Enterprise Value$4.00B

Total Cash (Recent Filing)$289.95M

Total Debt (Recent Filing)$52.79M

Price to Earnings (P/E)―

Beta-0.58

Next Earnings

Nov 05, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding53,145,008

10 Day Avg. Volume1,104,054

30 Day Avg. Volume1,342,200

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)7.37

Price to Sales (P/S)0.00

P/FCF Ratio-26.05

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-8.09K

Enterprise Value/Ebitda-25.48

Forecast

1Y Price Target

$113.78

Price Target Upside38.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

FDA ApprovalThe FDA's recent approval of Vykat XR for hyperphagia in Prader-Willi Syndrome was an inaugural event for this difficult-to-treat indication.

Market PotentialAssuming an EU approval, peak global Vykat XR sales are modeled at $2.6B, with potential for significant upside due to the urgent unmet need and absence of viable competitors.

Revenue PerformanceSoleno reported impressive Vykat XR revenue of $33MM in its first partial quarter, a remarkable beat that speaks to the urgent need for a hyperphagia treatment and Soleno management's commercial prowess.

Bears Say

Market CompetitionThe absence of viable competitors in the foreseeable future is crucial for Soleno's market position, yet any new entries could impact this advantage.

Price StrategyWhile management appears prepared to execute on a strong launch with a high price tag, the price point could potentially limit broader market adoption.

Soleno Therapeutics News

Soleno Therapeutics price target raised to $120 from $115 at TD Cowen

TD Cowen raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $115 and keeps a...

4d ago

SLNO

Soleno Therapeutics price target raised to $110 from $105 at Oppenheimer

Oppenheimer raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $105 and keeps an Outperform...

4d ago

SLNO

Soleno Therapeutics’ Earnings Call Highlights Success and Optimism

Soleno Therapeutics (($SLNO)) has held its Q2 earnings call. Read on for the main highlights of the call....

3d ago

SLNO

Soleno Therapeutics Reports Strong Q2 2025 Performance

Soleno Therapeutics ( ($SLNO) ) has released its Q2 earnings. Here is a breakdown of the information Soleno...

4d ago

SLNO

Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Soleno Therapeutics. The associated price...

4d ago

SLNO

Tyler Van Buren Reaffirms Buy Rating with Increased Sales Projections and Price Target for SLNO

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Soleno Therapeutics today and set a price...

19d ago

SLNO

Soleno Therapeutics price target raised to $121 from $105 at Baird

Baird analyst Brian Skorney raised the firm’s price target on Soleno Therapeutics (SLNO) to $121 from $105 and...

1M ago

SLNO

Soleno Therapeutics Announces Public Stock Offering

Soleno Therapeutics ( ($SLNO) ) has shared an announcement. On July 10, 2025, Soleno Therapeutics announced a public...

1M ago

SLNO

Soleno Therapeutics prices 2.35M sharesat $85.00 in public offering

Soleno Therapeutics (SLNO) priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at...

1M ago

SLNO

Soleno Therapeutics announces proposed $200M public offering

Soleno Therapeutics (SLNO) intends to offer and sell $200M of shares of its common stock in an underwritten...

1M ago

SLNO

Soleno Therapeutics sees Q2 VYKAT XR revenue $31M-$33M

Soleno Therapeutics (SLNO) announced certain preliminary unaudited financial and operational results for the three months ended June 30,...

1M ago

SLNO

Soleno Therapeutics price target raised to $115 from $108 at Stifel

Stifel raised the firm’s price target on Soleno Therapeutics (SLNO) to $115 from $108 and keeps a Buy...

1M ago

SLNO

Soleno Therapeutics highlights new data on VYKAT XR at United in Hope

Soleno Therapeutics (SLNO) highlighted new data on VYKATTM XR extended-release tablets, previously known as DCCR, at the 2025...

2M ago

SLNO

Soleno Therapeutics rumor highlighted in Betaville alert

The M&A-focused Betaville blog sent an alert to its subscribers related to a rumor regarding Soleno Therapeutics (SLNO),...

2M ago

SLNO

SLNO FAQ

What was Soleno Therapeutics’s price range in the past 12 months?

Soleno Therapeutics lowest stock price was $41.50 and its highest was $90.32 in the past 12 months.

What is Soleno Therapeutics’s market cap?

Soleno Therapeutics’s market cap is $4.38B.

When is Soleno Therapeutics’s upcoming earnings report date?

Soleno Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 86 days.

How were Soleno Therapeutics’s earnings last quarter?

Soleno Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.363.

Is Soleno Therapeutics overvalued?

According to Wall Street analysts Soleno Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Soleno Therapeutics pay dividends?

Soleno Therapeutics does not currently pay dividends.

What is Soleno Therapeutics’s EPS estimate?

Soleno Therapeutics’s EPS estimate is -0.06.

How many shares outstanding does Soleno Therapeutics have?

Soleno Therapeutics has 53,145,008 shares outstanding.

What happened to Soleno Therapeutics’s price movement after its last earnings report?

Soleno Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Soleno Therapeutics?

Currently, no hedge funds are holding shares in SLNO

Soleno Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-69.53%

Trailing 12-Months

Asset Growth

9.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Soleno Therapeutics

Soleno Therapeutics, Inc. (SLNO) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's primary product candidate is DCCR (Diazoxide Choline Controlled Release) tablets, which are in late-stage clinical development for the treatment of Prader-Willi Syndrome (PWS), a complex genetic neurobehavioral and metabolic disorder. Soleno is committed to improving the lives of patients with rare diseases through innovative solutions and therapies.

Soleno Therapeutics (SLNO) Earnings & Revenues

Historic Earnings Reports

SLNO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was overwhelmingly positive, with significant achievements such as the successful launch of Vykat XR, strong financial performance, and broad payer coverage. While there are some concerns about future inventory and revenue normalization, the overall outlook remains strong.View all SLNO earnings summaries

SLNO Stock 12 Month Forecast

Average Price Target

$113.78

▲(38.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","146":"$146","68.75":"$68.8","94.5":"$94.5","120.25":"$120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$81.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,68.75,94.5,120.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,90.53846153846153,95.07692307692308,99.61538461538461,104.15384615384616,108.6923076923077,113.23076923076923,117.76923076923077,122.3076923076923,126.84615384615384,131.3846153846154,135.9230769230769,140.46153846153845,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,88.13692307692308,90.27384615384615,92.41076923076923,94.5476923076923,96.68461538461538,98.82153846153847,100.95846153846153,103.09538461538462,105.2323076923077,107.36923076923077,109.50615384615385,111.64307692307693,{"y":113.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,85.61538461538461,85.23076923076923,84.84615384615384,84.46153846153847,84.07692307692308,83.6923076923077,83.3076923076923,82.92307692307692,82.53846153846153,82.15384615384616,81.76923076923077,81.38461538461539,{"y":81,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >